A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Ferreri, Kevin, Ph.D. Bookmark and Share

Ferreri, Kevin Ph.D. Research

Islet Cell Biology
Islet cell therapy is a very promising treatment for type 1 diabetes, but suffers from variability in the cell preparations used for transplantation. As part of this clinical program, my group has developed several new approaches for islet cell characterization, including metabolic parameters and gene expression profiling for evaluation of the islet cells prior to transplantation. Glucose stimulates insulin secretion from islets, and we are quantifying this response by the oxygen consumption rate and changes in cytochrome reduction. We have shown that these parameters have a high correlation with the ability of islets to reverse diabetes, and therefore identify “good” islet preparations. In a parallel study, we completed the gene expression profiling of several islet preparations and have identified a “gene signature” of islet quality. This geneset accurately predicts in vivo efficacy of transplanted islets, and we are developing a diagnostic test for islet function. We are also exploring the functional roles of these genes, which should lead to a better understanding of islet biology and better treatments for diabetics.
 
Circulating Nucleic Acids
A major difficult in both islet transplantation therapy and in diabetes in general is the lack of diagnostic tests that can be used to monitor islets in vivo. Based on the hypothesis that dying islet cells release cell debris into circulation, my group is measuring specific nucleic acids in the blood of our islet recipients and new onset diabetic patients. We have developed a highly sensitive and specific method to detect DNA from transplanted islets in the recipient’s circulation and find that the levels correlate with damage to the islet grafts. Recently we developed a similar test based on a unique DNA pattern we discovered for early detection of type 1 diabetes. These early markers of islet injury will allow timely intervention to prevent further loss of islet cells. We are building on these approaches to develop biomarkers for type 2 diabetes and diabetic complications.
 

Kevin Ferreri, Ph.D., Lab Members

Kevin Ferreri, Ph.D.
Associate Research Professor
626-256-HOPE (4673) ext.  65021
 
Mohamed El-Sayed, Ph.D.
Staff Scientist
626-256-HOPE (4673) ext.  31247
 
Alexander Kaye
Research Associate I
626-256-HOPE (4673) ext.  31218
 

Ferreri, Kevin, Ph.D.

Ferreri, Kevin Ph.D. Research

Islet Cell Biology
Islet cell therapy is a very promising treatment for type 1 diabetes, but suffers from variability in the cell preparations used for transplantation. As part of this clinical program, my group has developed several new approaches for islet cell characterization, including metabolic parameters and gene expression profiling for evaluation of the islet cells prior to transplantation. Glucose stimulates insulin secretion from islets, and we are quantifying this response by the oxygen consumption rate and changes in cytochrome reduction. We have shown that these parameters have a high correlation with the ability of islets to reverse diabetes, and therefore identify “good” islet preparations. In a parallel study, we completed the gene expression profiling of several islet preparations and have identified a “gene signature” of islet quality. This geneset accurately predicts in vivo efficacy of transplanted islets, and we are developing a diagnostic test for islet function. We are also exploring the functional roles of these genes, which should lead to a better understanding of islet biology and better treatments for diabetics.
 
Circulating Nucleic Acids
A major difficult in both islet transplantation therapy and in diabetes in general is the lack of diagnostic tests that can be used to monitor islets in vivo. Based on the hypothesis that dying islet cells release cell debris into circulation, my group is measuring specific nucleic acids in the blood of our islet recipients and new onset diabetic patients. We have developed a highly sensitive and specific method to detect DNA from transplanted islets in the recipient’s circulation and find that the levels correlate with damage to the islet grafts. Recently we developed a similar test based on a unique DNA pattern we discovered for early detection of type 1 diabetes. These early markers of islet injury will allow timely intervention to prevent further loss of islet cells. We are building on these approaches to develop biomarkers for type 2 diabetes and diabetic complications.
 

Lab Members

Kevin Ferreri, Ph.D., Lab Members

Kevin Ferreri, Ph.D.
Associate Research Professor
626-256-HOPE (4673) ext.  65021
 
Mohamed El-Sayed, Ph.D.
Staff Scientist
626-256-HOPE (4673) ext.  31247
 
Alexander Kaye
Research Associate I
626-256-HOPE (4673) ext.  31218
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • Equipping the immune system to fight cancer – a disease that thrives on mutations and circumventing the body’s natural defenses – is within reach. In fact, City of Hope researchers are testing one approach in clinical trials now. Scientists take a number of steps to turn cancer patients’ T cells – white b...
  • As treatments for lung cancer become more targeted and effective, the need for better technology to detect lung cancer mutations becomes increasingly important. A new clinical study at City of Hope is examining the feasibility of using blood and urine tests to detect lung cancer mutations, potentially allowing ...
  • When it comes to breast cancer risk, insulin levels may matter more than weight, new research has found. The study from Imperial College London School of Public Health, published in the journal Cancer Research, indicates that metabolic health – not a person’s weight or body mass index – increases breast cancer ...
  • No one ever plans to have cancer – and there’s never a good time. For Homa Sadat, her cancer came at a particularly bad time: just one year after losing her father to the pancreatic cancer he had battled for two years. She was working a grueling schedule managing three commercial office buildings. She’d just [&...
  • Patients at City of Hope – most of whom are fighting cancer – rely on more than 37,000 units of blood and platelets each year for their treatment and survival. Every one of those units comes from family, friends or someone who traded an hour or so of their time and a pint of their […]
  • Surgery is vital in the treatment of cancer – it’s used to help diagnose, treat and even prevent the disease – so a new colorectal cancer study linking a decrease in surgeries for advanced cancer to increased survival rates may raise more questions than it answers for some patients. The surgery-and-surviv...
  • Age is the single greatest risk factor overall for cancer; our chances of developing the disease rise steeply after age 50. For geriatric oncology nurse Peggy Burhenn, the meaning is clear: Cancer is primarily a geriatric condition. That’s why she is forging inroads in the care of older adults with cancer. Burh...
  • One of American’s great sportscasters, Stuart Scott, passed away from recurrent cancer of the appendix at the young age of 49. His cancer was diagnosed when he was only 40 years old. It was found during an operation for appendicitis. His courageous fight against this disease began in 2007, resumed again with an...
  • When Homa Sadat found a lump in her breast at age 27, her gynecologist told her what many doctors say to young women: You’re too young to have breast cancer. With the lump dismissed as a harmless cyst, she didn’t think about it again until she was at a restaurant six months later and felt […]
  • What most people call a “bone marrow transplant” is not actually a transplant of bone marrow; it is instead the transplantation of what’s known as hematopoietic stem cells. Such cells are often taken from bone marrow, but not always. Hematopoietic stem cells are simply immature cells that can ...
  • Doctors have long known that women with a precancerous condition called atypical hyperplasia have an elevated risk of breast cancer. Now a new study has found that the risk is more serious than previously thought. Hyperplasia itself is an overgrowth of cells; atypical hyperplasia is an overgrowth in a distorted...
  • Don’t kid yourself. Just because it’s mid-January doesn’t mean it’s too late to make resolutions for a happier, and healthier, 2015. Just consider them resolutions that are more mature than those giddy, sometimes self-deluded, Jan. 1 resolutions. To that end, we share some advice from Cary A. Presant, M.D., an ...
  • Sales and marketing executive Jim Murphy first came to City of Hope in 2002 to donate blood for a friend who was being treated for esophageal cancer. The disease is serious. Although esophageal cancer accounts for only about 1 percent of cancer diagnoses in the U.S., only about 20 percent of patients survive at...
  • Aaron Bomar and his family were celebrating his daughter’s 33rd birthday in September 2014 when he received alarming news: According to an X-ray taken earlier that day at an urgent care facility, he had a node on his aorta and was in danger of an aneurysm. Bomar held hands with his wife and daughter and s...
  • Explaining a prostate cancer diagnosis to a young child can be difficult — especially when the cancer is incurable. But conveying the need for prostate cancer research, as it turns out, is easily done. And that leads to action. Earlier this year, Gerald Rustad, 71, who is living with a very aggressive form of m...